PeriGen, an obstetrics information technology company, has named Matthew Sappern as its new CEO. The company, based at 700 Alexander Park, hired Sappern in January to replace former CEO Donald Deieso, who stepped down in August to join Arsenal Capital Partners.
A pioneer in advanced clinical decision support since 1995, PeriGen offers tools to provide real-time, interactive guidance at a patient’s bedside to facilitate the delivery of consistent care for mothers and babies. Its support tools encompass more than 6,000 protocols, best practices, and guidelines for obstetrics.
PeriGen’s advanced clinical decision support and fetal monitoring solutions are installed in hospitals and healthcare systems throughout North America.
“Hospital leaders are increasingly demanding tangible returns in shorter cycles on IT investment,” said Sappern, who was unavailable for a personal interview. “As this pressure mounts, the spotlight will swing quickly from broad enterprise systems with generic feature sets to departmental systems that leverage deep expertise to generate more focused, and immediate clinical and financial benefits.
“I know Perigen’s unique application of expert systems and clinical decision support is already addressing an acute need in the obstetrics space in a way that generates immediate, tangible returns — clinically and financially — for our hospital customers,” Sappern added.
PeriGen’s suite of products —designed for women and babies during the period just before and after childbirth — include the PeriBirth system for obstetrics, and the PeriCALM fetal monitoring system.
PeriBirth, a clinical decision support system (CDSS) is designed to help reduce obstetric errors, complications, and risk. A CDSS is an interactive computer software designed to assist physicians and other health professionals with decision making tasks, and determining diagnosis of patient data.
PeriBirth, which runs on a computer at the patient’s bedside, monitors the mother’s and baby’s changing conditions during childbirth, incorporating the mother’s specific medical history and giving real-time prompts, alerts, and suggestions to the clinical team.
For example, PeriBirth reports many common but potentially harmful labor and delivery conditions such as dangerous medication interactions and changes in the baby’s condition.
PeriCALM monitors contractions and fetal heart rate response during labor for changes in the mother’s labor progress, the strength of her contractions, and the baby’s reaction to her contractions over long periods of time.
Sappern, 45, was previously senior vice president of client sales at Allscripts, a $1.3 billion electronic medical records company. While at Allscripts, his client sales team achieved record bookings in 2011, according to a PeriGen press release.
Sappern joined Allscripts in 2010 after the company acquired Eclipsys, where he was senior vice president of professional services and directed the company’s consulting, implementation, and education and training services. In this role, Sappern reduced fixed cost of operations by 10 percent in 2008 and in 2009. He also established an offshore services division described as “industry leading” by analyst Piper Jaffray.
Sappern also established a methodology to reduce the time, complexity, and expense of implementing Eclipsys clinical software by 40 percent.
Sappern joined Eclipsys in 2003, as vice president of product development in the software engineering division. After three years, he was running 75 percent of the development operation and oversaw delivery of three enterprise software releases in record time for the company.
For 14 years prior to Eclipsys, Sappern worked in the media, technology, and healthcare sectors for companies such as Time Warner, Primedia, WebMD, and Young & Rubicam.
“Matt’s proven expertise in driving the growth of sophisticated, ground breaking healthcare IT products is a great fit for PeriGen,” said John Reardon, member of PeriGen’s board of directors, and managing director of Trident Capital.
“We are confident that as CEO Matt will significantly expand PeriGen’s market footprint so that the breadth and depth of its innovative, clinical decision support technologies can touch more patients and improve the bottom line at more healthcare systems in North America and around the world,” said David Jahns, a member of PeriGen’s board, and managing director of Galen Partners.
Both Trident and Galen are investors in PeriGen, along with Salmon River Capital.
Recently, MedStar Health, a nine-hospital system in the Washington, D.C. area, demonstrated how a PeriGen solution drove a 50 percent drop in the frequency and severity of obstetrics and labor and delivery claims during a presentation to the American Society for Healthcare Risk Management Annual Conference and Exhibition.
Executives from Banner Health, a 25-hospital system headquartered in Phoenix, AZ, also outlined how they achieved a reduction in self-insured reserves by $5.6 million per year after installing a PeriGen solution.
PeriGen also partners with global insurers and brokers such as Beazley PLC and Willis Group Holdings, who recognize the impact of PeriGen’s solutions in reducing risk and improving the quality of care delivered by offering premium reductions to insured hospitals that use certain PeriGen products, according to the PeriGen press release.
PeriGen, 700 Alexander Park, Suite 100, Princeton 08540; 609-228-7898; fax, 609-228-8224. Matthew Sappern, chairman and CEO. www.perigen.com.